(NASDAQ: MBX) Mbx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Mbx Biosciences's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast MBX's revenue for 2029 to be $1,477,357,198, with the lowest MBX revenue forecast at $1,477,357,198, and the highest MBX revenue forecast at $1,477,357,198. On average, 1 Wall Street analysts forecast MBX's revenue for 2030 to be $7,308,907,207, with the lowest MBX revenue forecast at $7,308,907,207, and the highest MBX revenue forecast at $7,308,907,207.
In 2031, MBX is forecast to generate $20,620,831,445 in revenue, with the lowest revenue forecast at $20,620,831,445 and the highest revenue forecast at $20,620,831,445.